0001704287
false
--12-31
0001704287
2023-07-21
2023-07-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
July 21, 2023
Bluejay Diagnostics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| delaware |
|
001-41031 |
|
47-3552922 |
(State or Other Jurisdiction of
Incorporation or Organization) |
|
(Commission File No.) |
|
(I.R.S. Employer
Identification No.) |
360 Massachusetts Avenue, Suite 203
Acton, MA 01720
(Address of principal executive offices and zip
code)
(844) 327-7078
(Registrant’s telephone number, including
area code)
(Former name or former address, if changed from
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c)). |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b)
of the Act:
|
Title of each class |
|
Trading Symbol (s) |
|
Name of each exchange on which
registered |
| Common Stock, par value $0.0001 per share |
|
BJDX |
|
The Nasdaq Stock Market LLC |
Item 3.03 Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K,
the information regarding the Reverse Stock Split (as defined herein) contained in Item 5.03 of this Current Report on Form 8-K is incorporated
by reference herein.
Item
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
At the Annual Meeting of Stockholders of Bluejay
Diagnostics, Inc. (the “Company”) held on June 14, 2023 (the “Annual Meeting”), the stockholders of the Company
approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to implement
a reverse stock split of the Company’s common stock, par value $0.0001 per share, with the ratio to be determined by the Board of
Directors (the “Board”) of the Company, at ratios of 1-for-5, 1-for-10, 1-for-20 or 1-for-25, respectively, and reduce the
number of authorized shares of Common Stock under the Charter from 100,000,000 shares to 30,000,000, 15,000,000, 7,500,000 and 6,000,000
respectively. Thereafter, on July 21, 2023, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”)
with the Secretary of State of the State of Delaware, to implement the 1-for-20 reverse split of its common stock (the “Reverse
Stock Split”) and to reduce the number of authorized shares of common stock under the Charter from 100,000,000 to 7,500,000. The
Reverse Stock Split will be effective as of 12:01 a.m. (Eastern Time) on July 24, 2023, and the Company’s common stock will begin
trading on The Nasdaq Capital Market on a post-split basis on July 24, 2023.
As a result of the Reverse Stock Split, every
twenty (20) shares of the Company’s issued and outstanding common stock, par value $0.0001, will be converted into one (1) share
of common stock, par value $0.0001, reducing the number of issued and outstanding shares of the Company’s common stock from approximately
20,466,890 shares to approximately 1,023,344 shares. The Company’s transfer agent Continental Stock Transfer & Trust Company
(“Continental”), will provide instructions to stockholders of record regarding the process of exchanging shares.
The Reverse Stock Split did not alter the par
value of the Company’s common stock or modify any voting rights or other terms of the common stock.
No fractional shares will be issued in connection
with the Reverse Stock Split. Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of
pre-Reverse Stock Split shares of the Company’s common stock not evenly divisible by twenty (20) will, in lieu of a fractional share,
be entitled, upon surrender to the exchange agent of certificate(s) representing their pre-split shares or upon conversion of their shares
held in book-entry, to receive a cash payment equal to the average closing price per share of the Company’s common stock during
the ten consecutive trading days ending on the trading day that is the second day immediately prior to the date on which the Reverse Stock
Split becomes effective, which cash payment shall not accrued, and shall be without, interest.
Continental will be issuing all of the post-split
shares through their paperless Direct Registration System, also known as “book-entry form”. Continental will hold the shares
in an account set up for the stockholder. All book-entry or other electronic positions representing issued and outstanding shares of the
Company’s common stock will be automatically adjusted. Those stockholders holding common stock in “street name” will
receive instructions from their brokers.
In addition, pursuant to their terms, a proportionate
adjustment will be made to the per share exercise price and number of shares issuable under all of the Company’s outstanding equity
awards and warrants to purchase shares of common stock, and the number of shares authorized and reserved for issuance pursuant to the
Company’s equity incentive plan will be reduced proportionately.
After the Reverse Stock Split, the trading symbol
for the Company’s common stock will continue to be “BJDX.” The new CUSIP number for the Company’s common stock
is 095633301.
The above description of the Certificate of Amendment
and the Reverse Stock Split is a summary of the material terms thereof and is qualified in its entirety by reference to the Certificate
of Amendment, a copy of which is attached hereto as Exhibit 3.1, as filed with the Secretary of State of the State of Delaware on July
21, 2023.
Item 5.07 Submission of Matters to a Vote of Security Holders.
To the extent required by Item 5.07 of Form 8-K,
the information regarding the Reverse Stock Split (as defined herein) contained in Item 5.03 of this Current Report on Form 8-K is incorporated
by reference herein.
Item 8.01 Other Events.
On July 21, 2023, the Company issued a press release
relating to the matters described in Item 5.03 above. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
Bluejay Diagnostics Inc. |
| |
|
| |
By: |
/s/ Kenneth Fisher |
| |
|
Kenneth Fisher |
| |
|
Chief Financial Officer |
Dated: July 21, 2023
4
Exhibit 3.1
CERTIFICATE OF AMENDMENT TO THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
BLUEJAY DIAGNOSTICS, INC.
Bluejay Diagnostics, Inc. (the “Corporation”),
a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Laws (the “DGCL”),
does hereby certify as follows:
FIRST: The name of the Corporation is Bluejay
Diagnostics, Inc., the date of filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware
was March 20, 2015, and the date of filing of its Amended and Restated Certificate of Incorporation with the Secretary of State of
the State of Delaware was October 22, 2021.
SECOND: The text currently constituting
the first sentence of Section 4.1 (Authorized Capital Stock) of Article IV (Capitalization) of the Amended and Restated Certificate
of Incorporation of the Corporation is amended and restated in its entirety to read as follows:
“The total number of shares of
all classes of capital stock, each with a par value of $0.0001 per share, which the Corporation is authorized to issue is TWELVE MILLION
FIVE HUNDRED THOUSAND (12,500,000) shares, consisting of (a) SEVEN MILLION FIVE HUNDRED THOUSAND (7,500,000) shares of common stock
(the “Common Stock”), and (b) FIVE MILLION (5,000,000) shares of preferred stock (the “Preferred Stock”).
Upon the effectiveness of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation, each
20 shares of Common Stock issued and outstanding at such time shall, automatically and without any further action on the part of the Corporation
or the holder thereof, be combined into one validly issued, fully paid and non-assessable share of Common Stock (the “Reverse
Stock Split”). The par value of the Common Stock following the Reverse Stock Split shall remain $0.0001 per share. No fractional
shares shall be issued, and, in lieu thereof, the Corporation shall pay cash equal to such fraction multiplied by the fair market value
of a share of Common Stock, as determined by the Board of Directors of the Corporation. Each certificate that immediately prior to the
effectiveness of this Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Corporation represented
shares of Common Stock (an “Old Certificate”) shall thereafter represent that number of shares of Common Stock into which
the shares of Common Stock represented by the Old Certificate shall have been combined, subject to the elimination of fractional share
interests as described above.”
THIRD: That resolutions were duly adopted
by unanimous written consent of the Board of Directors of the Corporation setting forth this amendment to the Amended and Restated Certificate
of the Corporation.
FOURTH: That said amendment was duly adopted
in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.
FIFTH: This Certificate of Amendment will become effective
at 12:01 A.m. Eastern Standard Time on July 24, 2023.
IN WITNESS WHEREOF, the Corporation has caused this Certificate
of Amendment to be signed on its behalf, by Neil Dey, its Chief Executive Officer, this 21st day of July, 2023.
| |
BLUEJAY DIAGNOSTIC, INC. |
| |
|
|
| |
By: |
/s/ Neil Dey |
| |
|
Name: Neil Dey |
| |
|
Title: Chief Executive Officer |
Exhibit 99.1
Bluejay Diagnostics
Announces Reverse Stock Split
ACTON, Mass., July 21,
2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company
developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the
Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-20 (the “Reverse
Stock Split”), with a corresponding reduction in the number of authorized outstanding number of shares of common stock from 100,000,000
to 7,500,000. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on July 24, 2023, and the Company’s common
stock will open for trading on The Nasdaq Capital Market on a post-split basis on July 24, 2023 under the Company’s existing trading
symbol, “BJDX.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 095633301.
The Reverse Stock Split
is being implemented to increase the per share trading price of the Company’s common stock for the purpose of ensuring a share price
high enough to comply with the minimum $1.00 bid price requirement for continued listing on The Nasdaq Capital Market.
At the effective time
of the reverse stock split, every twenty (20) shares of Bluejay common stock issued and outstanding will be combined into one (1) share
of common stock issued and outstanding, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding
common stock from approximately 20,466,890 shares to approximately 1,023,344 shares. No fractional shares of common stock will be issued
as a result of the reverse stock split and instead holders of Bluejay common stock will receive a cash payment in lieu of fractional shares
to which they would otherwise be entitled. The shares underlying the Company’s outstanding equity awards and warrants will also
be adjusted accordingly. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage
interest in the Company’s common stock, except for adjustments that may result from the treatment of fractional shares.
The Company has retained
its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as its exchange agent for the reverse
stock split. Stockholders with shares held in certificate form will receive from Continental instructions regarding the exchange of their
certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any
action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes.
Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding
procedures for processing the reverse stock split.
Additional information
regarding the reverse stock split is available in the definitive proxy statement filed with the U.S. Securities and Exchange Commission
on May 18, 2023 by the Company.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics
company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for triage
and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis triage, is designed to provide
accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier
and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the
Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking
statements in this press release include, without limitation, the expected nature and timing of the Company’s planned FDA submission
and related plans for clinical study amendment, whether the Company’s cash position will be sufficient to fund operations needed
to achieve regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such regulatory approval will actually
occur. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,”
“expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,”
“suggest”, “will,” and similar expressions. The Company has based these forward-looking statements on its current
expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions
and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions
and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. “Risk Factors”
in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company’s subsequent Quarterly
Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties,
and actual results and performance in future periods may not occur or may be materially different from any future results or performance
suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes
no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company
expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the
Company’s expectations of results or any future change in events.
Investor Contact:
Alexandra Schuman
LifeSci Advisors
alex@lifesciadvisors.com
t: 646-876-3647
v3.23.2
Cover
|
Jul. 21, 2023 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Jul. 21, 2023
|
| Current Fiscal Year End Date |
--12-31
|
| Entity File Number |
001-41031
|
| Entity Registrant Name |
Bluejay Diagnostics, Inc.
|
| Entity Central Index Key |
0001704287
|
| Entity Tax Identification Number |
47-3552922
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
360 Massachusetts Avenue
|
| Entity Address, Address Line Two |
Suite 203
|
| Entity Address, City or Town |
Acton
|
| Entity Address, State or Province |
MA
|
| Entity Address, Postal Zip Code |
01720
|
| City Area Code |
844
|
| Local Phone Number |
327-7078
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
| Trading Symbol |
BJDX
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
true
|
| Elected Not To Use the Extended Transition Period |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
| Name: |
dei_CurrentFiscalYearEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:gMonthDayItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Oct 2023 to Nov 2023
Bluejay Diagnostics (NASDAQ:BJDX)
Historical Stock Chart
From Nov 2022 to Nov 2023
